Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CCM Biosciences
AddedFeb 17, 2024
UpdatedJun 18, 2026
CCM Biosciences

CCM Biosciences

CCM Biosciences, a New Jersey-based biopharmaceutical company, innovates new drugs and diagnostic tests.

HQ
Mount Laurel, NJ, US
Founded
2010
Overview
Compare
Fundraising
Employees
Website

CCM Biosciences, founded in Mount Laurel, New Jersey, is a biopharmaceutical company dedicated to developing innovative drugs and companion diagnostic tests. The company's core mission is to advance healthcare through cutting-edge science and technology, focusing on various therapeutic areas. Their product pipeline includes novel treatments and diagnostic tools across multiple scientific disciplines such as RAS Sciences, PROTAC Sciences, Immune Sciences, Protein Upregulation, and Nanothera Sciences. CCM Biosciences aims to address unmet medical needs and improve patient outcomes globally.

Notable affiliated individuals include the management team, board of directors, and scientific advisors who bring extensive expertise in biotechnology and pharmaceuticals. The company is backed by Chakrabarti Capital Management (CCM), a seed-stage investor operating out of an Evergreen Fund. Key achievements of CCM Biosciences include the development of proprietary platforms for small molecule discovery, drug delivery, biologics discovery, and enzyme engineering. Their impact is marked by significant advancements in drug development and diagnostics, contributing to the broader healthcare landscape.

CCM Biosciences - Quick Facts

When was CCM Biosciences founded?

CCM Biosciences was founded in 2010.

Where is CCM Biosciences' headquarters located?

CCM Biosciences' headquarters is located in Mount Laurel, NJ, US.

When was CCM Biosciences' last funding round?

CCM Biosciences' most recent funding round was for $25M (USD) in August 2023.

How much has CCM Biosciences raised to-date?

As of Aug 30, 2023, CCM Biosciences has raised a total of $25M (USD).

How many employees does CCM Biosciences have?

CCM Biosciences has 50 employees as of Feb 4, 2024.

CCM Biosciences - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Development
Tags
  • Biotech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified